Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers

被引:33
|
作者
Nobashi, Tomomi W. [1 ]
Nishimoto, Yuko [1 ]
Kawata, Yujiro [1 ]
Yutani, Hidetaka [1 ]
Nakamura, Masaki [1 ]
Tsuji, Yuichi [1 ]
Yoshida, Atsushi [1 ]
Sugimoto, Akihiko [1 ]
Yamamoto, Takayuki [1 ]
Alam, Israt S. [2 ]
Noma, Satoshi [1 ]
机构
[1] Tenri Hosp, Dept Radiol, Nara, Japan
[2] Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford MIPS, Stanford, CA USA
来源
BRITISH JOURNAL OF RADIOLOGY | 2020年 / 93卷 / 1115期
关键词
ADVERSE EVENTS; POOLED ANALYSIS; DEATH; NIVOLUMAB; THERAPY; KL-6; IPILIMUMAB; BLOCKADE; SMOKING; RISK;
D O I
10.1259/bjr.20200409
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To investigate the clinical and radiological features of immune checkpoint inhibitor-related pneumonitis (ICI-P), a rare but serious pulmonary complication of cancer immunotherapy and to evaluate key differences between lung cancer (LC) and non-LC patients. Methods: 247 patients (LC, n = 151) treated with ICI for malignancies were retrospectively screened in a single institute. The number of patients, history of other immune-related adverse events (irAE), the onset, serum KL-6 levels, and chest CT features (types of pneumonitis, symmetry, laterality, location) were recorded for the ICI-P population and compared for LC and non-LC groups. Results: ICI-P was identified in 26 patients in total (LC, n = 19; non-LC, n = 7). The incidence of other irAE was significantly higher in ICI-P group (63%) compared with patients without ICI-P (34%) (p = 0.0056). An earlier onset of ICI-P was recorded in LC (78 days) compared to non-LC patients (186 days) (p = 0.0034). Serum KL-6 was significantly elevated only in the non-LC group when ICI-P was noticed (p = 0.029). Major CT findings of ICI-P, irrespective of primary disease, were organizing pneumonia pattern and ground glass opacities. LC patients commonly exhibited consolidation and traction bronchiectasis and were prone to asymmetrical shadows (p < 0.001). Non-LC patients were more likely to exhibit symmetrical infiltrations. A small fraction of both groups experienced relapse or moving patterns of ICI-P. Conclusion: ICI-P patients more often experienced other irAE prior to the development of ICI-P. The characteristics of ICI-P can differ in terms of the onset, KL-6 reliability, and chest CT findings between LC and non-LC patients. Advances in knowledge: In ICI-P patients, a history of other irAE can be more frequently observed. Differences in disease onset and radiological patterns between LC and non-LC patients might be helpful to make a diagnosis of ICI-P; however, longitudinal observation of chest CT scans is advised to observe the pneumonitis activity irrespective of cancer types.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Incidence of Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
    Poulose, Vijo
    CHEST, 2022, 161 (03) : E196 - E197
  • [2] Incidence of Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Response
    Atchley, William T.
    Rock, Little
    Alvarez, Carolina
    Saxena-Beem, Shruti
    Schwartz, Todd A.
    Ishizawar, Rumey C.
    Patel, Kunal P.
    Rivera, M. Patricia
    CHEST, 2022, 161 (03) : E197 - E197
  • [3] Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis
    Osaki, Megumu
    Arai, Toru
    Sumikawa, Hiromitsu
    Takimoto, Takayuki
    Takeuchi, Naoko
    Tamiya, Akihiro
    Okishio, Kyoichi
    Inoue, Yoshikazu
    ONCOLOGY, 2023, 101 (05) : 303 - 312
  • [4] Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
    Hao, Yuxuan
    Zhang, Xiaoye
    Yu, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis
    Larsen, Brandon T.
    Chae, June M.
    Dixit, Anuj S.
    Hartman, Thomas E.
    Peikert, Tobias
    Roden, Anja C.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (10) : 1331 - 1340
  • [6] Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
    Zhang, Qian
    Tao, Xiuli
    Zhao, Shijun
    Li, Ning
    Wang, Shuhang
    Wu, Ning
    DIAGNOSTICS, 2023, 13 (04)
  • [7] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Nishiyama, Osamu
    Shimizu, Shigeki
    Haratani, Koji
    Isomoto, Kosuke
    Tanizaki, Junko
    Hayashi, Hidetoshi
    Yamazaki, Ryo
    Oomori, Takashi
    Nishikawa, Yusaku
    Sano, Akiko
    Nakagawa, Kazuhiko
    Tohda, Yuji
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [8] Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
    Shu, Yang
    Xu, Wei
    Su, Rui
    Ran, Pancen
    Liu, Lei
    Zhang, Zhizhao
    Zhao, Jing
    Chao, Zhen
    Fu, Guobin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
    Chao, Yencheng
    Zhou, Jiebai
    Hsu, Shujung
    Ding, Ning
    Li, Jiamin
    Zhang, Yong
    Xu, Xiaobo
    Tang, Xinjun
    Wei, Tianchang
    Zhu, Zhengfei
    Chu, Qian
    Neal, Joel W.
    Wu, Julie Tsu-Yu
    Song, Yuanlin
    Hu, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (02) : 295 - +
  • [10] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Osamu Nishiyama
    Shigeki Shimizu
    Koji Haratani
    Kosuke Isomoto
    Junko Tanizaki
    Hidetoshi Hayashi
    Ryo Yamazaki
    Takashi Oomori
    Yusaku Nishikawa
    Akiko Sano
    Kazuhiko Nakagawa
    Yuji Tohda
    BMC Pulmonary Medicine, 21